• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Translation of Biomarkers into Clinical Utility

        互联网

        381
        Biomarkers are an integral part of a successful clinical drug development strategy and the associated commercialization of drug development programs. Biomarkers are used as necessary and as they are available to optimize drug development in early and late stage clinical trials. Achieving the full value of biomarkers hinges on the ability to successfully translate them for clinical use. Translation involves validation of the biomarker assay, as well as qualification of the biomarker with its intended clinical endpoint. Biomarkers must be planned and developed in a timely fashion, in order to meet the needs of clinical drug development and product approval as appropriate. Biomarkers come in many flavors, based on their intended use during early or late stage clinical development. Pharmacodynamic biomarkers and disease-related biomarkers may be used in early clinical development to optimize go/no-go decisions and to aid in appropriate dose and/or schedule selection. Disease-related biomarkers and pharmacogenomic biomarkers may be used to optimize later clinical development by facilitating the recognition of more homogeneous patient populations. Furthermore, biomarker research may be performed during clinical trials to optimize the development of future products or to identify markers that can enhance the commercial value of current products post-launch. The implementation of biomarkers into clinical development strategies should lead to more efficient drug development and improve the benefit-to-risk ratio for patients.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序